Осельтамивир (Oseltamivir)
Международное непатентованное наименование
Осельтамивир (Oseltamivir)
Торговое наименование
Tamiflu
Производитель, страна
Roche Holding, Switzerland
Механизм действия
Oseltamivir is a neuraminidase inhibitor, a competitive inhibitor of influenza's neuraminidase enzyme. The enzyme cleaves the sialic acid which is found on glycoproteins on the surface of human cells that helps new virions to exit the cell. Thus oseltamivir prevents new viral particles from being released.
Опыт использования
Oseltamivir is used for the prevention and treatment of influenza caused by influenza A and B viruses. FDA-approved since 1999.
Публикации COVID-19
Curr Med Chem. 2020 Apr 16. DOI: 10.2174/0929867327666200416131117.
Biomol Struct Dyn. 2020 Apr 16;1-6. DOI: 10.1080/07391102.2020.1752802.
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.004.
Клинические исследования
1.
Название протокола
A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19
Дата начала и окончания КИ
April 15, 2020 - November 30, 2020
Название организации, проводящей КИ
Rajavithi Hospital
Страны
Thailand
Фаза
III
Кол-во пациентов
320
2.
Название протокола
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment
Дата начала и окончания КИ
April 7, 2020 - November 30, 2020
Название организации, проводящей КИ
University of Health Sciences Lahore
Страны
Pakistan
Фаза
III
Кол-во пациентов
500
3.
Название протокола
An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.
Дата начала и окончания КИ
February 1, 2020 - July 1, 2020
Название организации, проводящей КИ
Tongji Hospital
Страны
China
Фаза
IV
Кол-во пациентов
400
4.
Название протокола
A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia
Дата начала и окончания КИ
February 1, 2020 - July 1, 2020
Название организации, проводящей КИ
Tongji Hospital
Страны
China
Фаза
III
Кол-во пациентов
60